Danish pharmaceutical firm Novo Nordisk said it has agreed to acquire the biotech company Cardior Pharmaceuticals, based in Hanover, Germany, for up to €1.03 billion ($1.01 billion), according to a joint announcement on Monday. Novo Nordisk, known primarily for its diabetes business and the weight-loss drugs Wegovy and Ozempic, intends to strengthen its presence in the field of cardiovascular diseases. The focus is particularly on a promising drug from Cardior for heart failure. Cardior was founded in 2016 as a spin-off from Hanover Medical School. The heart disease therapy developed by the st…